74843-14-4 Usage
Description
16(S)-Iloprost, also known as the S-isomer of Iloprost, is a synthetic analogue of Prostacyclin (PGI2). It is a pharmaceutical compound that has been developed to mimic the effects of the naturally occurring prostacyclin, which is a potent vasodilator and inhibitor of platelet aggregation. Due to its chemical structure and pharmacological properties, 16(S)-Iloprost has demonstrated significant therapeutic potential in various medical conditions.
Uses
Used in Pulmonary Arterial Hypertension Treatment:
16(S)-Iloprost is used as a vasodilator for treating pulmonary arterial hypertension (PAH). It helps to relax the blood vessels in the lungs, thereby reducing the resistance and pressure in the pulmonary arteries. This leads to improved blood flow and oxygenation, alleviating the symptoms of PAH and improving the patient's quality of life.
Used in Scleroderma Treatment:
In the context of scleroderma, 16(S)-Iloprost is used as an anti-ischemic agent to improve blood flow and reduce the symptoms of Raynaud's phenomenon, a common complication of scleroderma. It helps to prevent the constriction of blood vessels in response to cold temperatures or stress, thereby reducing the frequency and severity of Raynaud's attacks.
Used in Raynaud's Phenomenon Treatment:
16(S)-Iloprost is used as a vasodilator for the treatment of Raynaud's phenomenon, a condition characterized by the constriction of blood vessels in the fingers and toes, leading to pain, discoloration, and numbness. By promoting vasodilation, 16(S)-Iloprost helps to increase blood flow to the affected areas, reducing the severity and frequency of Raynaud's attacks.
Used in Ischemia Treatment:
16(S)-Iloprost is also used as an anti-platelet agent for the treatment of ischemia, a condition where there is a reduced blood supply to tissues or organs due to narrowed or blocked blood vessels. By inhibiting platelet aggregation and promoting vasodilation, 16(S)-Iloprost helps to improve blood flow and oxygenation to the ischemic tissues, reducing the risk of tissue damage and promoting healing.
Check Digit Verification of cas no
The CAS Registry Mumber 74843-14-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,4,8,4 and 3 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 74843-14:
(7*7)+(6*4)+(5*8)+(4*4)+(3*3)+(2*1)+(1*4)=144
144 % 10 = 4
So 74843-14-4 is a valid CAS Registry Number.
74843-14-4Relevant articles and documents
THERAPY FOR COMPLICATIONS OF DIABETES
-
, (2009/07/02)
A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
Method for treating resistant hypertension
-
, (2008/06/13)
A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.
Ein neuer Weg zu 6a-Carbacyclinen - Synthese eines stabilen, biologisch potenten Prostacyclin-Analogons
Skuballa, Werner,Vorbrueggen, Helmut
, p. 1080 - 1081 (2007/10/02)
-
